The crypto market cap is settled at around $2.4 trillion, followed by a 6.61% plunge. The majority of the assets are in red, going through extreme fear. MeanwhileThe crypto market cap is settled at around $2.4 trillion, followed by a 6.61% plunge. The majority of the assets are in red, going through extreme fear. Meanwhile

Shiba Inu (SHIB) in the Red Zone: Will It Find Support or Head for a Steeper Fall?

2026/02/05 21:47
3 min read
  • Shiba Inu trades at $0.0000062, falling 7%.
  • SHIB’s 24-hour trading volume has risen 23%.

The crypto market cap is settled at around $2.4 trillion, followed by a 6.61% plunge. The majority of the assets are in red, going through extreme fear. Meanwhile, the meme coin market kept to the same path and has dropped over 6.8%, sitting at $35 billion. Among the meme tokens, the dog-themed Shiba Inu (SHIB) has slipped by over 7.41% in the past 24 hours. 

The meme coin was trading at a high of around $0.000006775 in the morning hours. Eventually, with the bears pulling the momentum downward, the SHIB price fell and traded at a low of $0.000006206. At press time, it traded at $0.000006265, and its market cap is at $3.67 billion. Additionally, the trading volume has surged by over 23.81% to $197.82 million.

It is worth noting that the Shiba Inu’s burn rate is down by 100.00% in the last 24 hours. Notably, 410.75 trillion tokens were totally burnt from the initial supply. It leaves over 585.42 trillion tokens within the circulating supply. 

While analysing the recent price pattern of SHIB, the potent bears are found in the market. They could pull the price back to the support range at around $0.000006250. A deeper downside correction may trigger the death cross to unfold and drive the price below $0.000006235. 

If the long-lost uptrend is reclaimed by the bulls, Shiba Inu might find the nearest resistance level at $0.000006280. With a sturdy breakout, the bullish pressure would strengthen and could initiate the formation of the golden cross, likely to support the price action to climb above $0.000006295. 

Bears Take the Lead as SHIB Shows Signs of Technical Strain

SHIB’s Moving Average Convergence Divergence (MACD) line and signal line have crossed below the zero line, indicating a bearish mood. Also, the steep move downward confirms that the bearish trend is gaining strength, and it is interpreted as a potential continuation of downward price movement.

SHIB chart (Source: TradingView)

Besides, the Chaikin Money Flow (CMF) indicator, which assesses the money flow, suggests a slight positive flow as the value is at 0.02. As it is close to neutral, the momentum of Shiba Inu is weak, and the trend is not strongly bullish. Also, the buying pressure barely outweighs the selling pressure. 

The daily Relative Strength Index (RSI) is positioned at 30.29 displays that SHIB is approaching the oversold zone. This momentum significantly hints at weak momentum and toward a potential for a short-term relief bounce. Moreover, the Shiba Inu’s Bull Bear Power (BBP) reading rests at -0.00000053, signalling a mild bearish condition. With the weak downward pressure, the market is essentially near equilibrium, and this is taken as a minor negative sentiment.

Top Updated Crypto News

Are the Bulls Losing Control? As Momentum Pauses and Bears Probe, SUI Hits the Brakes After a 7% Slip

Market Opportunity
RedStone Logo
RedStone Price(RED)
$0.1834
$0.1834$0.1834
-1.92%
USD
RedStone (RED) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26